About Cancer Anorexia-Cachexia Syndrome Drug
Cancer anorexia-cachexia syndrome (CACS) is a multifactorial condition marked by progressive wasting. The loss of both skeletal muscle and fat distinguishes it from hunger. It's a metabolic syndrome in which glucose, protein, and lipid metabolism are all disrupted. Multifactorial pathophysiology has made some progress in recent years. Cancer syndrome is assumed to be the outcome of imbalanced interactions between inflammatory cytokines, neuropeptides, hormones, and tumor-derived substances, even though the etiology is unknown.
|Unit||Value (USD Million)|
Mergers and acquisitions, expansions, investments, new service launches, and collaborations are some of the companies' preferred market-exploration strategies. Players are expanding and acquiring businesses in new geographies to get a competitive edge through synergy. The major key players are contributing their share to increasing company growth. Industry leaders have improved their market position by investing more in research and having a more efficient distribution system. In December 2020, the University of Copenhagen, in partnership with Zealand University Hospital, began a clinical investigation on the effect of medical cannabidiol on lean body mass (cachexia) in patients receiving Oxaliplatin- or Paclitaxel-based chemotherapy. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Acacia Pharma Ltd (United Kingdom), Aeterna Zentaris Inc (United States), Aphios Corp (United Kingdom), Novartis AG (Switzerland), Incyte Corp (United States), Lakewood-Amedex Inc (United States), Obexia AG (Switzerland), PsiOxus Therapeutics Ltd (United Kingdom), RaQualia Pharma Inc (Japan) and Viking Therapeutics Inc (United States) are some of the key players that are part of study coverage.
AMA Research has segmented the market of Global Cancer Anorexia-Cachexia Syndrome Drug market by Type (NEO-1940, C-1889, DLN-101, Foxo1-nRNA, AVGN-7 and Others) and Region.
On the basis of geography, the market of Cancer Anorexia-Cachexia Syndrome Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Mechanism of Action, the sub-segment i.e. Appetite Stimulators will boost the Cancer Anorexia-Cachexia Syndrome Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutics, the sub-segment i.e. Progestogens will boost the Cancer Anorexia-Cachexia Syndrome Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Hospital will boost the Cancer Anorexia-Cachexia Syndrome Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Appetite Stimulators are expected to Grow Significantly
Market Growth Drivers:
Increasing prevalence of cancer and novel therapies and Rising pipeline products for cachexia cancer and increasing geriatric population
Limited reimbursement policies and stringent government regulations
High costs associated with treatment
Many major players are focused on R&D activities to develop highly effective novel drugs and The potential of reversing drug resistance
In April 2021, Actimed therapeutics ltd announced a license agreement with faraday pharmaceuticals for S-oxprenolol. Under the terms of the agreement, the company will be eligible for royalties on any future S-oxprenolol sales, and faraday will have the global rights to develop and commercialize S-oxprenolol for cancer cachexia.
Key Target AudienceCancer Anorexia-Cachexia Syndrome Drug Manufacturers, Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Traders/Suppliers & Distributors
About ApproachTo evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.